Welcome to our dedicated page for STERIS plc SEC filings (Ticker: STE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
STERIS plc filings document material events for an Ireland-incorporated operating company with ordinary shares traded as STE on the New York Stock Exchange. Recent Form 8-K reports cover results of operations and financial condition, attached earnings releases, director appointments and retirements, officer transition arrangements, and compensation-related amendments.
The filing record also identifies STERIS securities registered under Section 12(b), including ordinary shares and NYSE-listed senior notes due 2031 and 2051. These disclosures frame the company’s capital structure, governance actions, executive-compensation matters, and periodic operating-result announcements for its infection-prevention and life sciences business.
STERIS plc senior executive reports routine tax withholding on vested shares. On June 1, 2026, SVP & GM, AST Kenneth E. Kohler had 109 ordinary shares withheld to cover taxes on 373 restricted shares that vested, with the value based on the NYSE closing price on that date.
After this disposition, he directly holds 9,533 ordinary shares, of which 3,141 are still restricted as of June 1, 2026 and scheduled to lapse in stages through June 5, 2028. The filing also corrects previously misreported beneficial ownership amounts.
STERIS plc SVP & Chief HRO Mary Clare Fraser reported a routine tax-withholding share disposition. On June 1, 2026, 2,313 restricted shares vested, and 673 ordinary shares were withheld to cover taxes based on the NYSE closing market price that day. After this withholding, she directly holds 12,209 ordinary shares. As of June 1, 2026, 6,573 of these shares remain restricted, with restrictions scheduled to lapse in several tranches through June 5, 2028.
STERIS plc President and CEO Daniel A. Carestio reported a routine tax-related share disposition. On June 1, 2026, 1,254 ordinary shares were withheld from 4,308 restricted shares that vested, to cover taxes determined under applicable laws at the NYSE closing market price.
After this withholding, Carestio directly holds 49,842 ordinary shares. As of June 1, 2026, 28,746 of these are restricted shares scheduled to lapse over several dates through June 5, 2028, reflecting ongoing equity-based compensation rather than an open-market sale.
STERIS plc reported that Sr. Vice President and CFO Karen L. Burton had 99 ordinary shares withheld on June 1, 2026 to cover tax obligations on vested restricted stock. The Form 4 classifies this as a tax-withholding disposition, not an open-market trade.
The 99 shares were withheld from 340 restricted shares that vested on that date, valued at the NYSE closing market price. After this transaction, Burton directly holds 8,205 ordinary shares, of which 5,139 are restricted with scheduled lapses through October 1, 2028.
STERIS plc files its annual report describing a diversified infection-prevention business built around three segments: Healthcare, Applied Sterilization Technologies and Life Sciences. The company emphasizes consumables, capital equipment, contract sterilization and related services sold globally to hospitals, device makers and biopharma companies.
As of September 30, 2025, non‑affiliates held ordinary shares with an aggregate market value of $24,222.3 million, and 97,602,485 ordinary shares were outstanding as of May 27, 2026. Capital equipment backlog reached $490.7 million at March 31, 2026, reflecting higher orders in Healthcare and Life Sciences.
STERIS highlights strong quality and regulatory performance, reporting no FDA or regulatory enforcement actions and no Class I recalls in fiscal 2026, 2025 or 2024. The company also reports industry‑leading safety metrics, broad patent and trademark portfolios, and detailed environmental, social and governance initiatives, including greenhouse‑gas tracking and formal corporate responsibility governance.
STERIS plc filed an initial insider ownership report for director Pierre Boulud on Form 3. This filing establishes his status as a board member and brings his holdings, if any, under SEC disclosure rules, but it does not list any specific transactions or share amounts.
State Street Corporation reports beneficial ownership of 4,995,259 shares of STERIS PLC, representing 5.1% of the class as of 03/31/2026. The filing states shared voting power of 3,198,310 shares and shared dispositive power of 4,992,076.
The Schedule 13G lists multiple State Street-related entities as holders and is signed by a senior company officer on 05/12/2026. The filing discloses ownership on behalf of clients and affiliated investment-adviser and trustee entities.
STERIS plc reported strong results for fiscal 2026 and raised its outlook. Revenue from continuing operations grew 9% to $5.94 billion, while constant currency organic revenue increased 7%. As reported diluted EPS from continuing operations rose to $7.93, and adjusted EPS increased to $10.17.
Growth was broad-based: Healthcare revenue reached $4.21 billion, AST $1.14 billion, and Life Sciences $588.8 million. Net income from continuing operations was $782.3 million, and free cash flow improved to $982.9 million on operating cash flow of $1.34 billion.
For fiscal 2027, STERIS expects reported revenue to grow 7–8% and constant currency organic revenue 6–7%. Adjusted EPS is projected between $11.10 and $11.30, up 9–11% from fiscal 2026. The Board also authorized a new $1 billion share repurchase program, and capital expenditures of about $375 million will include a new sterility assurance plant in Mentor, Ohio.
STERIS plc reported changes to its Board of Directors. Long-serving director Richard C. Breeden will retire and not stand for reelection at the 2026 Annual General Meeting, with the company noting his decision is not due to any disagreement over operations, policies or practices.
The Board increased its size from nine to ten members and appointed Pierre Boulud, CEO of bioMérieux, as a director effective May 5, 2026. He brings experience in in vitro diagnostics, biopharma and strategy roles. Boulud will receive a prorated fee of $76,989 for the 2025-26 Board term, paid in career restricted stock units under STERIS’s Non-Employee Director Compensation Program.